Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Larazotide (AT-1001) peptide icon, one bubble per amino acidLarazotide (AT-1001)8 residuesGGVLVQPGEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Larazotide (AT-1001)

Beginner tier: 0.5 mg, 3x daily · clinical trials

Luminal activity ~1-4 hours half-life·Oral

Also known as: AT-1001, INN-202

Eight amino acids, taken as a capsule, designed to seal the gut barrier from the inside. Larazotide acetate (AT-1001) is a synthetic zonulin receptor antagonist that blocks tight junction disassembly triggered by gluten-derived gliadin peptides. In Phase 2b, 342 celiac patients on a gluten-free diet saw 26% fewer symptomatic days on the 0.5 mg dose. The Phase 3 trial failed at interim analysis in 2022, and the original developer went bankrupt a year later. Still, larazotide remains the most clinically advanced tight junction regulator ever tested; no injection needed, no systemic absorption, and a safety profile that matched placebo across every trial.

What Is Larazotide (AT-1001)?

A Phase 2b trial put 342 celiac patients on 0.5 mg three times daily, and symptomatic days dropped 26% compared to placebo. That single data point carried larazotide acetate (AT-1001, sequence GGVLVQPG, CAS 258818-34-7) through over a decade of clinical development.

Larazotide is a synthetic eight-amino-acid peptide originally derived from Vibrio cholerae's zonula occludens toxin. It blocks zonulin receptors on intestinal epithelial cells, preventing tight junction disassembly that gliadin peptides trigger after gluten exposure. The drug works entirely in the gut lumen. Systemic absorption is negligible, which accounts for its placebo-comparable safety profile across all trials.

Roughly 40% of celiac patients keep having symptoms despite strict gluten-free diet adherence. Larazotide was built for that population. You take a capsule 15 minutes before each meal, three times daily. No reconstitution. No needles. The drug reaches the duodenum and proximal jejunum, occupies zonulin binding sites, and keeps the paracellular pathway sealed.

The Phase 3 CedLara trial enrolled 525 patients but was discontinued in June 2022 when interim analysis showed the effect size couldn't reach statistical significance with a feasible sample size. 9 Meters Biopharma filed Chapter 7 bankruptcy in July 2023; assets sold to Interlude Biopharma Co. for $1.7 million. A newer thread of research points to MIS-C: Yonker et al. (2025)[1] ran a Phase 2a trial in 12 children and found faster SARS-CoV-2 spike antigen clearance with QID dosing. A Long COVID trial at Massachusetts General Hospital (NCT05747534) completed in June 2026 with 107 participants; no results were posted on ClinicalTrials.gov as of October 2026.

How Larazotide (AT-1001) Works

Gluten reaches the intestinal lumen, and gliadin peptides trigger zonulin release from enterocytes. Zonulin then binds epidermal growth factor receptor (EGFR) and protease-activated receptor 2 (PAR2) on the basolateral side of epithelial cells. That binding transactivates EGFR through PAR2, firing off phospholipase C. The downstream signaling generates inositol 1,4,5-triphosphate and diacylglycerol, which activate PKC-alpha.

PKC-alpha phosphorylates tight junction proteins, including ZO-1 and myosin 1C. Actin polymerization follows. The tight junction complex physically pulls apart, and paracellular permeability spikes. This is the cascade that drives celiac symptoms after gluten exposure.

Larazotide sits on zonulin binding sites before any of this starts. By occupying those receptors, it prevents the initial receptor activation. It also inhibits myosin light chain kinase (MLCK), reducing cytoskeletal tension on actin filaments. The combined effect is tight junction stabilization: ZO-1, occludin, and claudin proteins redistribute back to the cell membrane rather than getting pulled inward.

Because larazotide works in the luminal space and isn't absorbed systemically, it targets the disease mechanism at origin. No immune suppression. No off-target receptor activity outside the gut.

Larazotide (AT-1001) Benefits

  • Larazotide benefits center on intestinal barrier protection and symptom control for celiac disease patients who remain symptomatic on a gluten-free diet.
  • Sealed the gut barrier in controlled gluten challenges. Leffler et al. (2012)[2] showed larazotide blunted the intestinal permeability spike during deliberate gluten exposure.
  • 26% fewer symptomatic days in Phase 2b. Kelly et al. (2015)[3] tracked 342 celiac patients over 12 weeks; the 0.5 mg TID group also logged 31% more improved-symptom days versus placebo.
  • Oral capsule with no injection required. One of the few peptides you swallow rather than inject, which removes reconstitution, needles, and refrigeration from the equation entirely.
  • Negligible systemic absorption limits off-target effects. Larazotide acts in the intestinal lumen and gets degraded locally. Headache and UTI rates matched placebo across all trials (Kelly 2015, Leffler 2012).
  • Promotes redistribution of tight junction proteins. ZO-1, occludin, and claudin proteins move back to the cell membrane under larazotide's action, restoring paracellular barrier integrity.
  • Emerging MIS-C data from Yonker et al. (2025)[1]. A Phase 2a trial in 12 children showed faster clearance of circulating SARS-CoV-2 spike antigen and GI recovery, opening a potential new indication beyond celiac disease.

Larazotide (AT-1001): Science vs Community Consensus

Science Only
Scientific Evidence
Moderate
Based on 7 key studies·Phase 3

Oral 0.5 mg TID reduces GI symptoms in celiac disease patients on GFD.

Dosing studied: 0.5 mg TID (1.5 mg/day total), 15 min before meals: oral capsule only
Read the evidence (key study, limitations)

Phase 2b (n=342) showed 26% fewer symptomatic days and 31% more improved-symptom days vs. placebo. Phase 3 (n=525) failed to reach statistical significance at interim analysis (June 2022). Emerging Phase 2a data supports use in MIS-C (Yonker et al. 2025)[1]: faster spike antigen clearance and GI recovery. Long COVID trial (NCT05747534) completed June 2026 (n=107); no results posted as of October 2026.

Key Study

Kelly et al., Gastroenterology 2015 (Phase 2b, n=342, PMID 25683116); Yonker et al., Science Translational Medicine July 2025 (MIS-C Phase 2a, n=12, PMID 40737433)

Limitations

Phase 3 celiac trial (CedLara) failed. Original developer bankrupt (9 Meters, July 2023). IP now held by Interlude Biopharma Co. (patent assignments May and Dec 2024). No FDA approval. MIS-C data is n=12 only. Long COVID trial (NCT05747534) completed June 2026 with 107 enrolled; no results posted as of October 2026. Inverted dose-response (1 mg and 2 mg TID performed no better than placebo) limits escalation options.

Community Experience
Weak
3.0/5
Based on <50 self-reported anecdotal accounts across Phoenix Rising, Reddit, ME/CFS forums

Extremely niche community use.

Community dosing: 0.5 mg TID, typically 15 min before meals: matching clinical trial protocol
Read the reports (what users report 4, common issues 5)

Discussed primarily in ME/CFS and celiac disease forums. Oral convenience is the main appeal. Community sentiment shifted from hopeful (pre-2022) to cautiously disappointed after Phase 3 failure. Small subset self-experimenting for Long COVID/leaky gut.

What users report (4)
  • Oral administration: no injections, no reconstitution
  • Reduced bloating and abdominal pain in celiac patients
  • Anecdotal zonulin reduction in ME/CFS users
  • Clean safety profile: side effects comparable to placebo in trials
Common issues (5)
  • Phase 3 failed: no FDA approval path currently
  • Developer bankrupt; only raw research-grade API is available
  • High cost at lab-reagent pricing ($60+/day)
  • Inverted dose-response confuses users who assume more = better
  • Minimal community infrastructure compared to BPC-157 or TB-500
Science-Only Evidence

Community protocols directly mirror the Phase 2b clinical trial design (0.5 mg TID). The gap is volume: almost no organized community self-experimentation. Use is driven by patients with formal diagnoses (celiac, ME/CFS, Long COVID) seeking access to a clinically studied drug that never received approval.

Larazotide (AT-1001) Dosage Guide

Clinical TrialPhase 2b trial: larazotide acetate in celiac disease (CeliAction)Source (opens in a new tab)
LevelDoseFrequency
Beginner0.5 mg3x Daily
Moderate0.5 mg3x Daily
Aggressive0.5 mg3x Daily
Note:

Larazotide is oral. No vials, no bacteriostatic water, no syringes. You're swallowing a capsule, 0.5 mg, three times a day, 15 minutes before meals.

Timing matters more than most people expect. The capsule needs to be in the lumen before gliadin-derived peptides arrive. Taking it with food instead of before food likely reduces the protective window.

Formulation is the real variable here. Clinical trials used delayed-release capsules engineered to dissolve in the duodenum and proximal jejunum. Raw API powder dumped into a standard gelatin capsule may release in the stomach and never reach the target site. For research-grade powder, delayed-release encapsulation is not optional.

Don't escalate the dose. Phase 2b tested 0.5 mg, 1 mg, and 2 mg TID. The 1 mg and 2 mg groups performed no better than placebo. The working hypothesis is receptor saturation causing paradoxical loss of efficacy; 0.5 mg TID is the ceiling.

Store capsules at room temperature (20 to 25 degrees Celsius). Stable for 24 months when kept dry.

Cycling Protocol

On Period
12 weeks
Off Period
4 weeks

Clinical trials used 12-week continuous dosing periods. Larazotide is intended for ongoing daily use alongside a gluten-free diet, not as a short-term cycle. No evidence of tachyphylaxis or tolerance was observed during 12-week treatment periods. Long-term use patterns haven't been established in controlled trials.

Calculate your Larazotide (AT-1001) dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

Larazotide (AT-1001) Protocols by Goal

beginnerClinical Trial12 weeks on, 4 weeks off
Conservative initiation (optional)
Wk 1-2
0.25 mg · 3x daily · oral
Maintenance (clinical dose)
Wk 3-12
0.5 mg · 3x daily · oral

Expected: Gradual reduction in bloating and abdominal pain over 4-8 weeks; 50%+ reduction in weekly abdominal pain scores in Phase 2b responders by week 8-12

Monitor: Optional: lactulose/mannitol ratio at baseline and week 12 to objectively assess intestinal permeability change

How to Use Larazotide (AT-1001)

  1. 1
    Step 1

    Use larazotide acetate in delayed-release capsule form, 0.5 mg per capsule. The Certificate of Analysis should show HPLC purity of 98% or higher.

  2. 2
    Take one 0.5 mg capsule 15 minutes before breakfast

    Swallow whole with a full glass of water on an empty stomach. Do not open the capsule or chew it.

  3. 3
    Repeat before lunch

    Same timing: 15 minutes before eating, on an empty stomach, with water.

  4. 4
    Repeat before dinner

    Total daily intake is 1.5 mg (three capsules of 0.5 mg).

  5. 5
    Step 5

    Optional conservative start: some users begin at 0.25 mg TID for the first one to two weeks to assess GI tolerance before moving to 0.5 mg TID.

  6. 6
    Step 6

    Continue this protocol for 12 weeks alongside a strict gluten-free diet. Larazotide is an adjunct, not a replacement for dietary management.

  7. 7
    After 12 weeks, take a 4-week break to reassess symptoms

    No withdrawal or rebound effects were observed in clinical trials. Symptoms typically return gradually over 2 to 4 weeks after stopping.

  8. 8
    Step 8

    Storage: keep capsules at controlled room temperature (20 to 25 degrees Celsius). No refrigeration needed. No reconstitution step applies.

Note: larazotide is not an injectable. No syringe unit calculations apply. If you have raw powder rather than pre-made capsules, you'll need access to delayed-release encapsulation equipment or a compounding service. Standard gelatin capsules will release the drug in the stomach rather than the target site.

Alternative Routes

Oral capsule (delayed-release): primary route

N/A: this is the sole supported route

No injectable protocol exists or has been studied. Systemic absorption is negligible regardless of route: larazotide acts entirely in the intestinal lumen. No IV or SC formulation has been developed or tested.

Oral powder (non-encapsulated raw API)

Same nominal dose but uncertain luminal distribution; drug may release in stomach

Clinical formulations used delayed-release capsules to deliver drug specifically to the duodenum/proximal jejunum. Loose raw powder bypasses this targeting. Community reports of raw powder use are anecdotal with inconsistent outcomes.

Larazotide (AT-1001) Stacking Protocols

Works With

Avoid

NSAIDs (ibuprofen, naproxen, aspirin)

NSAIDs independently increase intestinal permeability via prostaglandin inhibition and direct mucosal damage: directly counteracting larazotide's barrier-protective mechanism. NSAID users were explicitly excluded from all clinical trials. Treat as a contraindication.

Do not combine
Concurrent antibiotics

Concurrent antibiotic use was an exclusion criterion in clinical trials. Antibiotics alter gut microbiome composition and intestinal permeability independently, confounding larazotide's effect.

Proton pump inhibitors / H2 blockers (omeprazole, famotidine)

Altered gastric pH from PPIs and H2 blockers can affect capsule dissolution timing and alter luminal distribution of larazotide in the duodenum/proximal jejunum.

Estimated Cost

Generic / Research
Lab-grade research chemical: ~$40/1 mg, ~$250/25 mg (~$8.33/mg bulk); Chinese bulk API ~$200/g (~$0.20/mg raw). At clinical dose (0.5 mg TID = 1.5 mg/day): lab-grade ≈$60/day; Chinese bulk API ≈$0.30/day raw material. Pre-formulated research combo: $199.99/60 caps (250 mcg N-Acetyl Larazotide + 250 mcg BPC-157 + 250 mcg KPV per cap; 250 mcg larazotide/day at one cap daily).

Pricing updated 2026-04-09

Larazotide (AT-1001) Side Effects

The Phase 3 CedLara trial (n=525) and its predecessor Phase 2b (n=342) both reported adverse event rates that were statistically indistinguishable from placebo. That's the headline, but the details matter because this drug's safety story is shaped more by what's absent than by what's present.

Headache occurred in roughly 5 to 7 percent of participants taking larazotide. The placebo group reported headache at the same rate. Urinary tract infections showed up at about 5 percent, again matching placebo. These are the two most commonly flagged events across all published trial data.

Mild GI symptoms (nausea, flatulence) appeared occasionally. Given that the entire study population had celiac disease and baseline GI symptoms, attributing any GI complaint specifically to larazotide is difficult. Trial investigators did not flag any GI adverse event as drug-related.

No serious adverse events were attributed to larazotide in any completed trial. No clinically meaningful changes in liver enzymes, kidney function, bone markers, hemodynamic measurements, or ECG parameters were observed. This clean profile is expected: larazotide isn't absorbed into the bloodstream. It acts in the intestinal lumen and gets degraded locally without reaching systemic circulation.

Pregnancy and breastfeeding represent a gap, not a clearance. No safety data exists for these populations. Clinical trials enrolled adults only; children under 18 were excluded. The MIS-C Phase 2a (Yonker 2025)[1] enrolled 12 pediatric patients with no reported serious adverse events, but that sample is far too small to draw safety conclusions for routine pediatric use.

Drug interactions are theoretical rather than documented. NSAIDs independently increase intestinal permeability and were excluded from clinical trials. Proton pump inhibitors and H2 blockers could alter capsule dissolution timing. Immunosuppressants like azathioprine and methotrexate have overlapping effects on intestinal immune responses; combined use was never studied.

When to stop: if GI symptoms worsen beyond your pre-treatment baseline, if you develop a new GI infection, or if antibiotic treatment becomes necessary. The trials excluded concurrent antibiotic use entirely.

Common Issues & Solutions

No improvement by week 8: Verify strict GFD adherence: even trace gluten cross-contamination can overwhelm larazotide's protective capacity. Audit all food sources, medications, and supplements for hidden gluten.

Formulation matters: Raw API powder without delayed-release capsule technology may release in the stomach before reaching the duodenum/proximal jejunum where larazotide must act. Avoid loose powder dosing.

Dose escalation urge: 1 mg and 2 mg TID showed no benefit vs. placebo in Phase 2b and may paradoxically reduce efficacy (receptor saturation hypothesis). 0.5 mg TID is the ceiling, not the starting point.

Timing errors: Taking capsule with food (rather than 15 min before meals) may reduce efficacy. Pre-meal dosing ensures drug is present in the lumen when gliadin-induced zonulin release occurs.

Off-weeks symptom return: Expected: benefits do not persist after discontinuation. No rebound or withdrawal observed, but intestinal permeability returns toward baseline within weeks of stopping.

Ask AI about this page

Ask AI for a second opinion on Larazotide (AT-1001) dosing and side effects

Contraindications

  • Pregnancy or breastfeeding (insufficient safety data in these populations)
  • Known hypersensitivity to larazotide acetate or any capsule excipients
  • Children under 18 years (clinical trials enrolled adults only)
  • Active gastrointestinal infections or acute inflammatory bowel disease flares
  • Patients who haven't been evaluated for celiac disease: larazotide is not a diagnostic tool

Drug Interactions

  • Immunosuppressants (azathioprine, methotrexate): overlapping effects on intestinal immune responses; combined use not studied
  • Oral medications with narrow therapeutic windows: changes in intestinal permeability could theoretically alter absorption of co-administered drugs
  • Proton pump inhibitors and H2 blockers: altered gastric pH could affect capsule dissolution timing
  • NSAIDs: these increase intestinal permeability independently and may counteract larazotide's barrier-protective effects
  • NSAIDs (ibuprofen, naproxen, aspirin)
  • NSAIDs independently increase intestinal permeability via prostaglandin inhibition and direct mucosal damage: directly counteracting larazotide's barrier-protective mechanism. NSAID users were explicitly excluded from all clinical trials. Treat as a contraindication.

Product Quality

Recommended Monitoring

TestWhenTarget
Lactulose/mannitol ratio (intestinal permeability urine test)Baseline before starting; repeat at week 12Normal ratio <0.030; >50% reduction from personal baseline is a meaningful response signal
GI symptom diary / Celiac Symptom Index (CSI)Weekly throughout protocolNot listed
Serum zonulin (optional)Baseline and week 12Not listed
Lactulose/mannitol ratio (intestinal permeability urine test)

Objective measure of tight junction integrity used in clinical trials. Confirms functional response independent of subjective symptom reporting.

GI symptom diary / Celiac Symptom Index (CSI)

The CSI tool was used in Phase 2b to define responders. Weekly abdominal pain scoring allows objective comparison to trial responder threshold (≥50% reduction by weeks 8-12).

Serum zonulin (optional)

Anecdotally tracked in ME/CFS self-experimentation. Note: commercial serum zonulin assays have significant cross-reactivity issues; interpret results cautiously. No validated target range for clinical use.

Larazotide (AT-1001) Before and After

Days 1-7

Begin taking 0.5 mg capsules three times daily before meals. No immediate symptom changes expected. Larazotide works locally in the gut and requires consistent dosing to stabilize tight junctions.

Weeks 2-4

Some patients began noticing reduced bloating and abdominal discomfort during this period in clinical trials. Intestinal permeability markers may start to shift.

Weeks 4-8

Measurable symptom improvement becomes more apparent. In Phase 2b, the 0.5 mg group showed a 26% decrease in symptomatic days by this point. Abdominal pain scores typically show the clearest response.

Weeks 8-12

Peak clinical benefit observed in trials. Patients achieving response typically show a 50% or greater reduction in weekly average abdominal pain scores. Symptom improvement plateaus.

Month 3+

Long-term maintenance data is limited since trials capped at 12 weeks. Continued use alongside a gluten-free diet is the intended model. No tolerance development was seen during trial durations.

What to Expect

Days 1 through 7, tolerance establishment: The drug distributes through the intestinal lumen and starts occupying zonulin receptors. Don't expect symptom changes in the first week. Steady-state luminal concentrations probably establish within days given the short activity window. Headache (5 to 7 percent) and UTI (about 5 percent) were the only notable adverse events in trials, both matching placebo rates. Some users report mild nausea or flatulence that resolves within a few days.

Weeks 2 through 4, early barrier stabilization: Tight junction proteins (ZO-1, occludin, claudins) begin redistributing back to the cell membrane. Intestinal permeability markers start shifting if you're tracking lactulose/mannitol ratios. A minority of users notice subtle reductions in post-meal bloating. Most describe the improvement as gradual and hard to pin down at this stage. ME/CFS users report mixed results.

Weeks 4 through 8, measurable symptom improvement: This is where the Phase 2b data gets concrete. The 0.5 mg TID group logged 26% fewer symptomatic days by this window. Abdominal pain scores showed the clearest response. Users who respond describe this as the most noticeable period: reduced bloating, less cramping, more consistent stool patterns. Non-responders typically decide to stop here.

Weeks 8 through 12, peak clinical benefit: Responders in Phase 2b hit 50% or greater reduction in weekly average abdominal pain scores. The trial also recorded 31% more improved-symptom days versus placebo. Benefits plateau; further gains beyond week 8 to 10 are unlikely. Headache and UTI rates stayed at placebo levels through the full 12 weeks.

Off-weeks (weeks 13 through 16), washout and reassessment: No tolerance, tachyphylaxis, or withdrawal was observed in any 12-week trial. Intestinal permeability drifts back toward pre-treatment baseline after stopping. Symptoms return gradually over 2 to 4 weeks. Some users skip the formal off period and dose continuously, citing no tolerance buildup, but long-term safety data for continuous use doesn't exist.

Detailed Timeline: Science vs Community

Days 1-7
Science

Drug distributes to intestinal lumen and begins occupying zonulin receptors. No measurable symptomatic changes expected; steady-state luminal concentrations likely reached within days.

Community

Most users report no noticeable changes in week 1. Occasional mild GI adjustment (nausea, flatulence) at placebo-comparable rates; resolves within days.

Weeks 2-4
Science

Tight junction protein redistribution (ZO-1, occludin, claudins) back to cell membrane. Intestinal permeability markers begin to shift. Some Phase 2b patients noted reduced bloating in this window.

Community

Minority of users report subtle reduction in post-meal bloating and abdominal discomfort. Most describe gradual, difficult-to-attribute improvement. ME/CFS users report mixed results.

Weeks 4-8
Science

Phase 2b: 26% decrease in symptomatic days by week 8 in the 0.5 mg TID group. Abdominal pain scores show clearest response. Permeability markers continue improving.

Community

Users who respond describe this as the most noticeable window. Reduced bloating, less frequent cramping, more consistent stool patterns. Non-responders typically stop here.

Weeks 8-12
Science

Phase 2b peak: 50%+ reduction in weekly average abdominal pain scores in responders; 31% more improved-symptom days. Benefit plateaus: further improvement unlikely beyond this window.

Community

Responders report stable, maintained symptom control. No further incremental gains beyond week 8-10 is the common experience.

Off-weeks (weeks 13-16)
Science

No tolerance, tachyphylaxis, or withdrawal observed in 12-week trials. Intestinal permeability returns toward pre-treatment baseline after stopping. No long-term data beyond 12 weeks in controlled trials.

Community

Gradual return of symptoms within 2-4 weeks of stopping. No rebound phenomenon. Some users skip formal off periods and dose continuously, citing no tolerance development; long-term safety unknown.

Pharmacokinetics

Half-Life
2h
Bioavailability
Negligible systemic absorption: larazotide acts entirely within the intestinal lumen and is degraded locally without entering the bloodstream
Tmax
~1 hour (peak luminal concentrations in duodenum/proximal jejunum in porcine model)
Data Confidence
moderate

Source: Estimated luminal activity duration of 1-4 hours based on porcine model showing peak duodenal concentrations at ~1 hour post-dose; larazotide is not systemically absorbed so plasma half-life is not applicable

Pharmacokinetics: Active Dose Over Time

t½ = Luminal activity ~1-4 hours (not systemically absorbed)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
8
Sequence
GGVLVQPG
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers

Who Should Consider Larazotide (AT-1001)

  • Celiac disease patients with persistent GI symptoms despite strict gluten-free diet adherence
  • Individuals with confirmed increased intestinal permeability (elevated lactulose/mannitol ratio)
  • Celiac patients seeking an adjunct therapy to complement their gluten-free diet
  • Adults with non-celiac gluten sensitivity and documented barrier dysfunction
  • Researchers studying tight junction regulation and zonulin pathway interventions

Related Peptides

What Changed for Larazotide (AT-1001)

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 20267 Citations

References

  1. [1]Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome (MIS-C) (Yonker et al., Sci Transl Med 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge (Leffler et al., Am J Gastroenterol 2012) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet (Kelly et al., Gastroenterology 2015) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Store capsules at controlled room temperature (20-25°C), stable for 24 months
After Reconstitution
Not applicable: oral capsule formulation, no reconstitution needed
Temperature
20-25°C (68-77°F)

Frequently Asked Questions

The inverted dose-response in Phase 2b is real and nobody has a definitive explanation. Hypotheses include receptor saturation causing a paradoxical effect, or over-stabilization of tight junctions interfering with normal nutrient transport. No clinical evidence supports using any dose above 0.5 mg TID, and the Phase 3 program moved to 0.25 mg and 0.5 mg only.

There's actual data supporting this. The 2012 Leffler et al. gluten challenge trial specifically tested this scenario and found larazotide could blunt the spike in intestinal permeability during controlled gluten challenges. Whether acute-use works as well as continuous dosing hasn't been compared head-to-head though.

All clinical trials enrolled only confirmed celiac patients on a gluten-free diet. The zonulin antagonist mechanism could theoretically apply to any tight junction dysregulation, but no RCT has tested it in non-celiac populations. Academic research is exploring NAFLD, acute pancreatitis, and Long COVID applications, but none have finished Phase 2.

No. It was tested only as an adjunct to an existing GFD, never as a replacement. Every participant in Phase 2b maintained strict GFD throughout the trial. Using it to enable gluten consumption is not supported by any data.

9 Meters filed Chapter 7 bankruptcy in July 2023 and assets were sold to Interlude Biopharma Co. for $1.7M. No new Phase 3 program has been announced. Some academic interest continues around MIS-C and Long COVID applications, but commercial celiac development appears stalled.